

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	<b>Application Number</b>	10/061,944	
	<b>Filing Date</b>	February 1, 2002	
	<b>First Named Inventor</b>	Schall, Thomas J.	
	<b>Group Art Unit</b>	1646	
	<b>Examiner Name</b>		
<b>Total Number of Pages in This Submission</b>	1	<b>Attorney Docket Number</b>	019934-0032100

RECEIVED

AUG 20 2002

TECH CENTER 1800/2900


<b>ENCLOSURES (check all that apply)</b>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement copies of 12 cited references <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
<b>Remarks</b>		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>		
<b>Firm and Individual name</b>	Townsend and Townsend and Crew LLP Scott L. Aussenhus Reg. No. 42,271	
<b>Signature</b>		
<b>Date</b>	08/13/02	

<b>CERTIFICATE OF MAILING</b>		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: August 13, 2002		
<b>Typed or printed name</b>	Maisie C. Livengood	
<b>Signature</b>		<b>Date</b> August 13, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
DE 7079106 v1

BEST AVAILABLE COPY



Whereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

PATENT  
Attorney Docket No.: 019934-003210US

*Handwritten initials: H4 MW*

RECEIVED

AUG 20 2002

TECH CENTER 1600/2500

On August 13, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Maisie C. Livengood  
Maisie C. Livengood

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Thomas J. Schall et al.

Application No.: 10/061,944

Filed: February 1, 2002

For: Chemomagnetic Retrieval of CMV  
and CMV Infected Cells

Examiner:

Art Unit: 1646

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

**BEST AVAILABLE COPY**

Respectfully submitted,



Scott L. Ausenh  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:mcl

DE 7078503 v1

BEST AVAILABLE COPY



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	10/061,944
Filing Date	February 1, 2002
First Named Inventor	Schall, Thomas J.
Art Unit	1646
Examiner Name	
Attorney Docket Number	019934-003210US

RECEIVED

AUG 20 2002

TECH CENTER 1600/2900

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	CHEE, M.S., et al.; Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169; <i>Current Topics in Microbiology and Immunology</i> ; 1990; pp. 125-169; Volume 154	
	B	CHEE, M.S., et al.; Human cytomegalovirus encodes three G protein-coupled receptor homologues; <i>Nature</i> ; 19 April 1990; pp. 774-777; Volume 344	
	C	FINE, JAY S., et al.; Evaluation of Chemokine- and Phlogistin-Mediated Leukocyte Chemotaxis Using an in Vivo Sponge Model; <i>Inflammation</i> ; 2000; pp. 331-346; Volume 24, No. 4	
	D	FORD-HUTCHINSON, A.W., et al.; Leukotriene B <sub>4</sub> , Polymorphonuclear Leukocytes and Inflammatory Exudates in the Rat; <i>Prostaglandins</i> ; July 1984; pp. 13-27; July 1984; Volume 28, No. 1	
	E	GAO, JI-LIANG, et al; Human Cytomegalovirus Open Reading Frame US28 Encodes a Functional $\beta$ Chemokine Receptor; <i>The Journal of Biological Chemistry</i> ; November 18, 1994; pp. 28539-28542; Volume 269, No. 46	
	F	GARRETT, R.; Assessment of nonsteroidal anti-inflammatory drug combinations by the polyurethane sponge implantation model in the rat; <i>Annals of the Rheumatic Diseases</i> ; 1983; pp. 439-442; Volume 42	
	G	HARRISON, JEFFREY K.; Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia; <i>Proc. Natl. Acad. Sci. USA</i> ; September 1998; pp. 10896-10901; Volume 95	
	H	IUVONE, TERESA, et al.; Differential effect of L-NAME and S-methyl-isothiourea on leukocyte emigration in carrageenin-soaked sponge implants in rat; <i>British Journal of Pharmacology</i> ; 1997; pp. 1637-1644; Volume 121	
	I	MIDDLETON, MARJORIE J., et al.; Functions of Purified Mouse Neutrophils Isolated From Gelatin Sponges; <i>Journal of Leukocyte Biology</i> ; 1989; pp. 461-466; Volume 46	
	J	NEOTE, KULDEEP, et al.; Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor; <i>Cell</i> ; February 12, 1993; pp. 415-425; Volume 72	
	K	NISHIYORI, ATSUSHI, et al.; Localization of fractalkine and CX <sub>3</sub> CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?; <i>FEBS Letters</i> ; 1998; pp. 167-172; Volume 429	
	L	ZLOTNIK, ALBERT, et al.; Recent Advances in Chemokines and Chemokine Receptors; <i>Critical Reviews™ in Immunology</i> ; 1999; pp. 1-47; Volume 19	

BEST AVAILABLE COPY

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
DE 7078503 v1